AU · rank #6 · 2026-09-04
THC
NYSE · $20.82B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.379 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.64 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 15 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.171 |
| Analyst upside Consensus target $285.10 | +8.2% |
| Momentum acceleration 3-month minus 12-month momentum. | +53.37% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.55 |
| Gross margin TTM | +41.7% |
| 52w high | $283.05 |
| Market cap (USD) | $20.82B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Tenet Healthcare operates acute care hospitals and a large ambulatory surgery center platform, generating ~$22B in annualized revenue with high-20s operating margins and growing higher-acuity volumes.
Rationale
The analyst_upside signal is reinforced by a massive 43.5% Q2 earnings beat, a ~$295M EBITDA guidance raise, 89% revision agreement among 20 analysts, and $3.36 in upward EPS revisions over 60 days — consensus is still catching up to a structurally improved earnings trajectory.
Material risks
- 1ACA exchange reimbursement deterioration is the most concrete thesis-breaker — management explicitly flagged exchange headwinds that, if they deepen via policy shifts or enrollment declines, could rapidly reverse the volume and margin tailwinds driving the guidance raise.
- 2Zero insider buying over 90 days despite a 50%+ EPS surge and strong momentum acceleration is a notable divergence — insiders are not confirming the bullish analyst narrative with their own capital, which warrants monitoring for conviction asymmetry.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.